CM-272 is a potent dual inhibitor targeting both histone deacetylases (HDACs) and bromodomain and extra-terminal (BET) proteins, making it a promising candidate in epigenetic cancer therapy. It has shown significant antitumor activity in preclinical models, particularly in hematological malignancies such as acute myeloid leukemia (AML) and lymphoma. By simultaneously disrupting two key epigenetic pathways, CM-272 effectively suppresses oncogene expression and induces cell cycle arrest and apoptosis in cancer cells. Its ability to overcome resistance mechanisms observed with single-target epigenetic drugs highlights its potential as a more effective therapeutic option. Research is ongoing to evaluate its efficacy in solid tumors and to optimize its pharmacokinetic profile for clinical development.